| Aripiprazole (Abilify®) | Off-label use for adults and pediatric patients | FDA approved for acute manic and mixed episodes in adults and pediatric patients ages 10 to 17 (as monotherapy and adjunct to lithium or valproate) | FDA approved for bipolar I disorder in adults and pediatric patients ages 10 to 17 (as monotherapy and adjunct to lithium or valproate) |
|
| Asenapine (Saphris®) | | FDA approved for acute manic and mixed episodes (as monotherapy and adjunct to lithium or valproate) | |
|
| Carbamazepine (Carbatrol®, Equetro®, Tegretol®, Tegretol®-XR) | Off-label use | Equetro is FDA approved for acute manic and mixed episodes | Off-label use |
|
| Chlorpromazine (Thorazine®) | | FDA approved | Off-label use |
|
| Clonazepam (Klonopin®) | | Off-label use | |
|
| Clozapine (Clozaril®) | | | Off-label use |
|
| Divalproex sodium delayed release (Depakote®), divalproex sodium extended release (Depakote® ER) | Off-label use | FDA approved for acute mania | Off-label use |
| Valproate sodium injectable (Depacon®) | | FDA approved for acute mania | |
| Valproic acid (Depakene®), valproic acid delayed release (Stavzor®) | Off-label use | FDA approved for acute mania | Off-label use |
|
| Gabapentin (Neurontin®) | | | Off-label use |
|
| Haloperidol (Haldol®) | | Off-label use | Off-label use |
| (Haldol® Decanoate) | | | Off-label use |
|
| Lamotrigine (Lamictal®, Labileno®, Lamictin®) | Off-label use | Off-label use as an adjunctive and second-line therapy | FDA approved for bipolar I disorder |
|
| Lithium (Eskalith®, Eskalith CR®, and others) | Off-label use | FDA approved | FDA approved |
|
| Olanzapine (Zyprexa®) | Off-label use | FDA approved for acute manic and mixed episodes (as monotherapy and adjunct to lithium or valproate) | FDA approved |
|
| Olanzapine-fluoxetine combination (Symbyax®) | FDA approved | | Off-label use |
|
| Oxcarbazepine (Trileptal®) | Off-label use | Off-label use | Off-label use |
|
| Quetiapine fumarate (Seroquel®, Seroquel XR®) | FDA approved | FDA approved for acute manic and mixed episodes associated with bipolar I disorder (as monotherapy and adjunct to lithium or divalproex) | FDA approved for patients with bipolar I disorder (as adjunct to lithium or divalproex) |
|
| Risperidone (Risperdal®) | Off-label use | FDA approved for acute manic and mixed episodes (as monotherapy and adjunct to lithium or valproate) | Off-label use |
| (Risperdal® Consta®) | | | FDA approved for bipolar I disorder (as monotherapy and adjunct to lithium or valproate) |
|
| Thioridazine (Mellaril®) | | Off-label use | Off-label use |
|
| Topiramate (Topamax®) | | | Off-label use |
|
| Trifluoperazine (Stelazine®) | | Off-label use | Off-label use |
|
| Ziprasidone (Geodon®) | Off-label use | FDA approved for acute manic and mixed episodes | FDA approved for patients with bipolar I disorder as adjunct to lithium or valproate |
|
| Antidepressant agents (various) | Off-label usea | | |
| Maprotiline (Ludiomil®) | FDA approved | | |